Publication | Closed Access

Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial

MedicineMito End-2GynecologyRecurrent Endometrial CancerCancer TreatmentOncologyRadiation OncologyGynecology OncologyEndocrine-related Cancer